Next Article in Journal
Osmotically Activated Anion Current of Phycomyces Blakesleeanus—Filamentous Fungi Counterpart to Vertebrate Volume Regulated Anion Current
Previous Article in Journal
Performance of a Real-Time PCR Assay for the Detection of Five Candida Species in Blood Samples from ICU Patients at Risk of Candidemia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoF
Volume 9
Issue 6
10.3390/jof9060636
jof-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Antibodies as Models and Tools to Decipher Candida albicans Pathogenic Development: Review about a Unique Monoclonal Antibody Reacting with Immunomodulatory Adhesins

by
Jordan Leroy
1,2,3,
Karine Lecointe
1,2,
Pauline Coulon
3,
Boualem Sendid
1,2,3,*,
Raymond Robert
4 and
Daniel Poulain
1,2,*
1
CNRS, UMR 8576, UGSF—Unité de Glycobiologie Structurale et Fonctionnelle, University of Lille, F-59000 Lille, France
2
INSERM U1285, University of Lille, F-59000 Lille, France
3
CHU Lille, Laboratoire de Parasitologie-Mycologie, F-59000 Lille, France
4
Kalidiv ZA, La Garde Bâtiment 1 B, Allée du 9 Novembre 1989, F-49240 Avrillé, France
*
Authors to whom correspondence should be addressed.
J. Fungi 2023, 9(6), 636; https://doi.org/10.3390/jof9060636
Submission received: 27 April 2023 / Revised: 20 May 2023 / Accepted: 29 May 2023 / Published: 31 May 2023
Browse Figure
Review Reports Versions Notes

Abstract

:
Candidiasis, caused mainly by Candida albicans, a natural commensal of the human digestive tract and vagina, is the most common opportunistic fungal infection at the mucosal and systemic levels. Its high morbi–mortality rates have led to considerable research to identify the molecular mechanisms associated with the switch to pathogenic development and to diagnose this process as accurately as possible. Since the 1980s, the advent of monoclonal antibody (mAb) technology has led to significant progress in both interrelated fields. This linear review, intended to be didactic, was prompted by considering how, over several decades, a single mAb designated 5B2 contributed to the elucidation of the molecular mechanisms of pathogenesis based on β-1,2-linked oligomannoside expression in Candida species. These contributions starting from the structural identification of the minimal epitope as a di-mannoside from the β-1,2 series consisted then in the demonstration that it was shared by a large number of cell wall proteins differently anchored in the cell wall and the discovery of a cell wall glycoplipid shed by the yeast in contact of host cells, the phospholipomannan. Cytological analysis revealed an overall highly complex epitope expression at the cell surface concerning all growth phases and a patchy distribution resulting from the merging of cytoplasmic vesicles to plasmalema and further secretion through cell wall channels. On the host side, the mAb 5B2 led to identification of Galectin-3 as the human receptor dedicated to β-mannosides and signal transduction pathways leading to cytokine secretion directing host immune responses. Clinical applications concerned in vivo imaging of Candida infectious foci, direct examination of clinical samples and detection of circulating serum antigens that complement the Platelia Ag test for an increased sensitivity of diagnosis. Finally, the most interesting character of mAb 5B2 is probably its ability to reveal C. albicans pathogenic behaviour in reacting specifically with vaginal secretions from women infected versus colonized by this species as well as to display higher reactivity with strains isolated in pathogenic circumstances or even linked to an unfavourable prognosis for systemic candidiasis. Together with a detailed referenced description of these studies, the review provides a complementary reading frame by listing the wide range of technologies involving mAb 5B2 over time, evidencing a practical robustness and versatility unique so far in the Candida field. Finally, the basic and clinical perspectives opened up by these studies are briefly discussed with regard to prospects for future applications of mAb 5B2 in current research challenges.

1. Introduction

Candidiasis (either mucocutaneous or systemic) is an opportunistic infection caused mainly by Candida albicans, a yeast and natural commensal of the human digestive tract and vagina [1,2,3]. Unlike true pathogens, the presence of yeasts alone does not indicate their pathogenic character, which depends essentially on the susceptibility of the host and the expression of pathogenicity factors by some yeast strains [4]. It is therefore essential to have markers associated with pathogenicity to understand the mechanisms of infection [5,6] and to diagnose these infections as accurately as possible [7]. The development of hybridoma technology/advent of monoclonal antibodies (mAbs) led to considerable progress in answering some of these questions [8]. Among the mAbs developed, one generated in the mid-1980s (mAb 5B2) [9] allowed us to make considerable progress in understanding the mechanisms of pathogenesis and also contributed to the diagnosis of candidiasis and the tracing of more pathogenic strains. This unique contribution is based on more than 50 basic and clinical publications.
This review aims to discuss the linear nature of the development and use of this mAb in order to better understand the pathogenesis of candidiasis and its diagnosis. Information from current research suggests that many discoveries still have to be made in this field.

2. Basic Studies

2.1. Immunochemical Identification of mAb 5B2 Epitopes, Their Carrier Molecules and Genes Involved in Their Synthesis

Unlike many mAbs generated from the immunisation of mice with killed yeasts or molecules extracted from yeasts, mAb 5B2 was generated from an experimental infection in a rat [9].
As the epitope was found to be present in mannan, a major C. albicans cell wall polysaccharide both quantitatively and qualitatively, its precise nature was determined through a series of immunobiochemical studies concerning this molecule. These studies consisted of sequential depolymerisation and nuclear magnetic resonance analysis and were based around the impressive pioneering structural studies conducted in Japan by Prof. Suzuki’s group on Candida mannans or, more exactly, phosphopeptidomannans (PPMs), focusing on the so-called antigenic factors allowing Candida species or serotype identification by direct agglutination [10,11,12]. The 5B2 epitope was identified among the β-1,2-linked mannoside series [13,14,15,16,17]. These structures are rare in the living world and are expressed in large quantities in the most pathogenic species of the genus Candida, namely C. glabrata and C. tropicalis, which are isolated second and third, respectively, after C. albicans from human disease. A considerable amount of information on β-1,2 oligomannosides has been gathered by S. Suzuki’s group according to their relation with antigenic factors [18] and expression in different strains depending on growth conditions showing important changes related to pH [19] and temperature [20], triggering the yeast to hyphal transition [21]. An impressive synthesis gathering all this information was presented in a review published in 2012 [12]. The precise identification of the 5B2 epitope showed reactivity against a minimal degree of polymerisation of two β-1,2 linked mannoside residues, thus corresponding to antigenic factor 5 and in part antigenic factor 6 [22].
Western blot profiles revealed that the 5B2 epitope was expressed on a large number of C. albicans molecules [23] distributed among very high relative molecular weight polydispersed material containing large amounts of polysaccharides and bands with lower molecular weight and better resolution in gels, corresponding to mannosylated proteins. These patterns were observed for several other pathogenic Candida species, with each having specific mapping of the 5B2 epitope [24]. In turn, an analysis of these profiles led to the discovery of concanavalin A-unreactive glycoconjugates with no protein moiety and to the identification of a glycolipid we named phospholipomannan (PLM) [25]. PLM was then studied extensively and characterised as a cell wall molecule belonging to the manno-inositol-phosphoceramide family [17,26,27,28,29].
Refinement of the methods of extraction of C. albicans cell wall mannoproteins based on the knowledge of their mode of insertion (PPM, glycosylphosphatidylinositol (GPI)-anchored proteins with internal repeats (PIR proteins and secreted proteins)) led to a complete mapping of the molecules containing the 5B2 epitope, among which were well known “proteins” described as virulence factors, including Hwp1 and HSP 70 [30]. mAb 5B2 mapping of β-mannose epitopes in the mannoproteins of different cell wall fractions of mutants defective in the map kinase pathway revealed its importance in regulating the exposure of different surface anomery and modulation of the immune response [31].
Finally, mAb 5B2 contributed uniquely to the discovery and identification of the nine members of the gene family encoding β-mannosyl transferases (BMTs 1–9), responsible for the sequential addition of β-Mans on different carrier molecules. This has significantly improved our understanding of the β-Man biosynthetic pathway in C. albicans [32]. Further definition of BMT functions was achieved through sequential deletion in the strain BWP17 by PCR gene targeting. Briefly, β-Man transfer is under the control of BMTs 1 and 3 for the acid-stable fraction of PPM and BMTs 2, 3 and 4 for the acid-labile fraction. None of these four enzymes act on PLM, nevertheless BMTs 5 and 6 are specifically involved in the β-mannosylation of PLM. Concerning the O-mannosylation of cell wall mannoproteins, this depends on BMTs 1 and 3 [33,34,35,36]. Gene deletion of BMTs 7–9 was inconclusive and has not been the subject of specific studies to date. Only transcriptome analysis carried out to decipher C. albicans iron homeostasis mentions BMT 7 and BMT 9 in alternative genetic programs adapting to blood stream versus gut environments [37,38].
Recent developments in this area of research concern a highly pathogenic Candida species that emerged simultaneously in different countries worldwide with the characteristics of antifungal resistance and high virulence, leading to high rates of mortality among patients in intensive care units. This species, C. auris, was also shown to synthesise β-Mans [39].
Analysis of the distribution of the mAb 5B2 epitope confirmed high expression in some strains, placing C. auris in the same group as C. albicans, C. tropicalis and C. glabrata, namely the most pathogenic Candida species (Leroy et al., unpublished data to date). Experimentally, it has been shown that an IgG3 mAb specific for a β-1,2 linked mannotriose described as protective against C. albicans [40] also protected mice against C. auris infection [41]. Addressing the general topic of the interplay between Candida and human antibodies, an impressive study demonstrated that C. albicans was able to shape the antibody repertoire though CARD9-dependent induction of host-protective antifungal IgG, including against C. auris [42]. On the fungal side, a mechanism of yeast surface modulation of antigens, including β-mannosides, able to direct macrophage responses was discovered to be under the control of C. albicans mitochondrial proteins [43]. In our view, these fascinating findings from this area of research deserve to be highlighted.

2.2. Cytological and Histopathological Analysis of mAb 5B2 Epitope Expression

In parallel to the identification of these molecules, mAb 5B2 was involved in studies aimed at localising the expression of 5B2 epitopes. At the population level, direct immunoperoxidase staining of C. albicans colonies grown on agar revealed an unforeseen complex expression of the epitope distributed according to different sectors [44]. Immunofluorescence and confocal microscopy studies revealed a complex expression due to the multiplicity of molecules differently expressing the epitope on yeasts and hyphal forms at a given time in the cell cycle [45]. Among these, shedding of PLM from the cell wall on contact with host cells was demonstrated unambiguously [46,47]. mAb 5B2 was used early on in histopathological studies to assess the presence of invasive foci of Candida in different clinical situations and experimental models [48]. At the gut level, it was used to assess colonisation by yeast species expressing β-mannosides and to identify host and yeast backgrounds modulating intestinal interactions [49,50].
At the ultrastructural level, transmission electron microscopy studies on C. albicans ultrathin liquid nitrogen frozen sections probed with 5B2 directly coupled to gold particles showed its localisation within cytoplasmic vesicles merging with the cell membrane and crossing the cell wall through channels [51,52]. The merging of these channels at the cell wall surface corresponded to the “patchy” distribution of β-Man epitopes reported by other authors in immunofluorescence studies [53].

2.3. Contribution of mAb 5B2 to the Analysis of the Immunological Interface between C. albicans and 5B2 Epitopes or Molecules Expressing These Epitopes—Identification of the Ligands and Triggering Consequences

As a counterpart to the identification of the 5B2 epitope and the C. albicans molecules expressing these specific motifs, mAb 5B2 was involved in experiments to assess the properties of these molecules. In these immunobiological studies, mAb 5B2 was the probe used as a reference. One of the major findings was the identification of Galectin-3 (Gal-3) as the mammalian receptor for β-mannosides [45,46,47,54,55,56,57,58,59,60,61,62,63]. Although research on Gal-3, known as Mac2 antigen, was limited at this time [60], Gal-3 is now established as a lectin playing an important role in numerous human diseases; its important pleiotropic roles have generated more than 5000 papers. Interestingly, regarding Candida pathogenesis, circulating levels of Gal-3 appear to be markers of both infection and inflammation [64], a duality compatible with its ability to predict the recurrence of Crohn’s disease after surgery associated with persistent inflammation and C. albicans colonisation [65]. Regarding relative importance of Gal-3 among other C. albicans receptors, its discovery at the end of the 1990s was among the first of a long list of what has been called later Pathogens Recognition Receptors (PRRs) as a counterpart of fungal Pathogen Associated Microbial Patterns (PAMPs). Only mannose receptor was identified at this time [66,67], as early as in the 1980s, so that differentiating at this time a and β mannose binding was important. To our knowledge, apart from MBL, which was described simultaneously in 2000 [68], other major receptors were identified later: Dectin-1 in 2001 [69,70,71]; first TLRs in 2002 [72,73]; DC-Sign in 2003 [74]; Dectin-2 in 2006 [75,76]. Comprehensive reviews regularly synthesized the importance of these interactions in shaping the host immune response [77,78,79]. Regarding the modulation liable to be linked to Gal-3, a reason to delve into this notion is that the presence of β-1,2-mannosides in N-linked mannan reduces the production of inflammatory cytokines by dendritic cells [80]. This seems of pathophysiological relevance since the morphological transformation of Candida conidia into hyphae form is characterized by a decrease in the amount of phosphodiesterified acid-labile β-1,2-linked manno-oligosaccharides, whereas the amount of acid-stable β-1,2 linkage-containing side chains does not change [21]. The corollary to these findings may be that Candida variants reacting with mAb 5B2 are unable to induce a robust proinflammatory and an appropriate mechanism of antigen presentation. This should be noticed because dendritic cells show a unique pattern of C-lectin type receptors to carry out non-opsonic phagocytosis and produce cytokines that tailor the microenvironment in the immune synapsis to initiate the adaptive immune response. This disappearance of β-Man is of importance regarding unmaking of α-Mans. This topic relates to the so-called ASCA, human antibodies revealed by S. cerevisiae mannan allowing the diagnosis of Crohn’s disease but generated by C. albicans pathogenic phase [81]. These antibodies are indeed anti-oligomannose antibodies reacting with α-1,3 mannose at the non-reducing end of 2 or 3 α-1,2 linked mannose. Besides Crohn’s disease, ASCA are associated with a strong inflammatory response in a wide range of human diseases, most of which are associated with fungal dysbiosis and a C. albicans overgrowth [82].

2.4. Construction of mAb 5B2 Epitope Synthetic Analogues (β-1,2 Oligomannoside Series) and Analysis of Their Biological and Immunological Properties

With regard to the difficulties in producing β-1,2 oligomannosides by sequential degradation of C. albicans PPM, synthetic analogues were produced by chemical synthesis. mAb 5B2 was used to assess their conformity with natural products through the development of chemical synthesis steps. These synthetic probes mimicking adhesins were shown to prevent C. albicans colonisation in experimental mouse models [62]. When coupled to biotin sulfone, it was possible to detect specific antibodies either on microspheres by multi-analyte profiling technology (Luminex) or surface plasmonic analysis [83]. A recent paper involving mAb 5B2 used the same technology to determine the structural basis for protective epitope specificity and to discriminate the humoral responses of infected versus colonised patients [84].
In a similar approach aimed at identifying the structures mimicking β-Mans, a phage library expressing random peptides was screened with mAb 5B2. The application of this phage display methodology led to the isolation of peptides presenting with the same specificity as β-Mans in terms of adhesion and immunogenicity [85].

3. Clinical Studies

3.1. Diagnosis of Systemic Infections by the Detection of mAb 5B2 Epitopes

Alongside the mass of information accumulated at the basic/cognitive level, medical applications were investigated early on based on the assumption that the epitopes recognised were important for pathogenesis and that they were consistently expressed.
The first step consisted of demonstrating the presence of 5B2 epitopes circulating in the serum of experimentally infected animals and patients in order to prove the growth of yeasts in tissues. The technology used was immunogold silver staining (IGSS), an elegant, sensitive and highly specific method developed from the direct coupling of mAbs to gold particles used for ultrastructural localisation of antigens [48,86].
Another investigation concerned the ability of mAb 5B2 to reveal Candida infectious foci in living organism by radioimaging. In an innovative study at the time, the coupling of mAb 5B2 to iodine 131 demonstrated that it revealed pathognomic features of organ involvement in infected animals [87]. The ability of mAb 5B2 to detect antigens released by Candida in the sera of infected patients that were not detected by mAb EB-CA1 used in the Candida Platelia antigen test increased the sensitivity of antigen detection for rapid diagnostic purposes [88,89]. An immunomagnetic separation method involving magnetic beads coated with 5B2 was shown to be effective at concentrating Candida from blood [90,91]. From a technological point of view, the multiplicity of methods involving mAb 5B2 for immunodetection (IGSS, radiolabelling, coupling to latex particles, sandwich ELISA) has demonstrated the robustness and reliability of this probe.

3.2. Analysis of mAb 5B2 Epitope Expression as an Epidemiological Marker of the Virulence of C. albicans Strains

Flow cytometry analysis of strains grown in different conditions demonstrated the extent of regulation of surface β-mannoside expression modifying virulence properties [92], in concordance with early investigations with mAb 5B2 showing its ability to differentiate C. albicans strains according to the circumstances of their isolation (i.e., commensal vs. pathogenic situations). Indeed, when colonies isolated in the clinical mycology laboratory were tested by direct agglutination with purified mAb 5B2, strains isolated from blood cultures showed significantly higher expression of the epitope compared to strains isolated from other sites. This property was confirmed regardless of the geographical area of isolation (Lille, France; D. Poulain or Leicester, UK; F. C. Odds) [44]. Thus, mAb 5B2 appeared to be a possible marker of the pathogenic behaviour of C. albicans. Almost three decades later, this ability was confirmed in a larger collaborative study; 385 strains were studied by ELISA to assess the level of mAb 5B2 surface expression. Impressively, higher expression of the mAb epitope was significantly associated with higher mortality [93].

3.3. mAb 5B2 in the Particular Setting of Vaginal Infections

The vaginal mucosa is the clinical site where information about the pathogenic behaviour of C. albicans strains would be important to assess since C. albicans is both a frequent commensal and an opportunistic pathogen at this site. Vulvovaginal candidiasis occurs in 75% of women during their lifetime and up to 10% of women will suffer from recurrent infections that are particularly difficult to eradicate.
An initial study consisted of testing strains isolated from the vagina of symptomatic or asymptomatic women using latex particles according to a methodology developed by R. Robert [94]. This study revealed significantly higher agglutination scores in women exhibiting clinical signs of vaginal candidiasis (unpublished results; Catherine Bernard, Medical doctor thesis, 1995, Medical School, Lille, France).
These results prompted a second collaborative study assessing the reactivity of antigens released by C. albicans into vaginal fluid using an immunochromatographic test. According to the principles of the test, only molecules bearing 5B2 epitopes are retained from the vaginal sample. These migrate until the presence of the immune complex is captured in a band, revealing a positive test. This test had a negative predictive value of 98.6%, a positive predictive value of 96.6% and an efficiency of 98% in differentiating 130 symptomatic women with vaginitis from 75 asymptomatic controls, irrespective of the number of yeasts isolated in each category [95]. This confirmed the ability of mAb 5B2 to preferentially reveal C. albicans pathogenic behaviour.
In order to synthetically illustrate and complement this review, two addendums are provided. Figure 1 schematizes the different complementary achievements gained over time in basic and clinical research by using mAb 5B2. Table 1 lists the technologies involving mAb 5B2, emphasizing the unique robustness and flexibility of this probe.

4. Conclusions

Among the large number of mAbs generated against C. albicans to date, mAb 5B2 has been established as the tool that has made the most significant contribution to the complex analysis of C. albicans β-Man virulence factors. Concomitantly, it is also able to detect circulating antigens with diagnostic relevance in coherence with its epidemiological/pathophysiological ability to react more effectively with pathogenic species and pathogenic strains. To conclude on some perspectives concerning the use of mAb 5B2, it is clear on the clinical side that its ability to diagnose VVC, which is a worldwide medical and economic problem [98], should deserve to be confirmed by larger studies. Concerning more basic investigations, the balance between expression of b- and a-mannosides mAb 5B2 reveals probably one of the more interesting characters of C. albicans flexibility which has been overseen. The previously discussed balance between pro-inflammatory and anti-inflammatory responses triggered by this α/β shift perfectly fits with the elegant concept of the damage network proposed by A. Casadeval and A.L Piroski [99] to explain the different clinical features of candidiasis. In this respect, mAb 5B2 differences in C. albicans strains isolated from pathophysiological niches recall old epidemiological studies on serotypes A and B [10,11]. Large scale clinico-epidemiological mAb 5B2 typing of strains isolated in different pathological circumstances, i.e., IBDs versus invasive, would be worthwhile to assess the validity of this hypothesis.

Author Contributions

Conceptualization, D.P. and B.S.; writing—original draft preparation, J.L., K.L., P.C., B.S., R.R. and D.P.; writing—review and editing, J.L., K.L., P.C., B.S., R.R. and D.P.; supervision, D.P.; project administration, not relevant; funding acquisition: not relevant. All authors have read and agreed to the published version of the manuscript.

Funding

INSERM.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We are indebted to the members of the Lille INSERM Candida group who have contributed to construct the β-Man story with 5B2, with the particular mention of P.A. Trinel who left us too early. Finally, special thanks on this occasion to Val Hopwood, our dedicated English editor for a long time, who generated mAb 5B2 during her post-doc in Lille.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Poulain, D. Candida albicans, plasticity and pathogenesis. Crit. Rev. Microbiol. 2015, 41, 208–217. [Google Scholar] [CrossRef]
  2. Pappas, P.G.; Lionakis, M.S.; Arendrup, M.C.; Ostrosky-Zeichner, L.; Kullberg, B.J. Invasive candidiasis. Nat. Rev. Dis. Primers 2018, 4, 18026. [Google Scholar] [CrossRef]
  3. Lopes, J.P.; Lionakis, M.S. Pathogenesis and virulence of Candida albicans. Virulence 2022, 13, 89–121. [Google Scholar] [CrossRef] [PubMed]
  4. Polke, M.; Hube, B.; Jacobsen, I.D. Candida survival strategies. Adv. Appl. Microbiol. 2015, 91, 139–235. [Google Scholar] [CrossRef] [PubMed]
  5. Swidergall, M.; LeibundGut-Landmann, S. Immunosurveillance of Candida albicans commensalism by the adaptive immune system. Mucosal Immunol. 2022, 15, 829–836. [Google Scholar] [CrossRef] [PubMed]
  6. Gow, N.A.; van de Veerdonk, F.L.; Brown, A.J.; Netea, M.G. Candida albicans morphogenesis and host defence: Discriminating invasion from colonization. Nat. Rev. Microbiol. 2011, 10, 112–122. [Google Scholar] [CrossRef]
  7. Wickes, B.L.; Romanelli, A.M. Diagnostic Mycology: Xtreme Challenges. J. Clin. Microbiol. 2020, 58, e01345-19. [Google Scholar] [CrossRef]
  8. Rudkin, F.M.; Raziunaite, I.; Workman, H.; Essono, S.; Belmonte, R.; MacCallum, D.M.; Johnson, E.M.; Silva, L.M.; Palma, A.S.; Feizi, T.; et al. Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis. Nat. Commun. 2018, 9, 5288. [Google Scholar] [CrossRef]
  9. Hopwood, V.; Poulain, D.; Fortier, B.; Evans, G.; Vernes, A. A monoclonal antibody to a cell wall component of Candida albicans. Infect. Immun. 1986, 54, 222–227. [Google Scholar] [CrossRef]
  10. Suzuki, S. Structural Investigation of Mannans of Medically Relevant Candida Species; Detremination of Chemical Structures of Antigenic Factors, 1, 4,5, 6, 9 and 13b. In Fungal Cells in Biodefense Mechanisms; Suzuki, S., Suzuki, E.M., Eds.; Saikon Publishing Co., Ltd.: Tokyo, Japan, 1997; pp. 1–15. [Google Scholar]
  11. Suzuki, M.; Fukazawa, Y. Immunochemical characterization of Candida albicans cell wall antigens: Specific determinant of Candida albicans serotype A mannan. Microbiol. Immunol. 1982, 26, 387–402. [Google Scholar] [CrossRef]
  12. Shibata, N.; Kobayashi, H.; Suzuki, S. Immunochemistry of pathogenic yeast, Candida species, focusing on mannan. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2012, 88, 250–265. [Google Scholar] [CrossRef] [PubMed]
  13. Faille, C.; Wieruszeski, J.M.; Michalski, J.C.; Poulain, D.; Strecker, G. Complete 1H- and 13C-resonance assignments for D-mannooligosaccharides of the beta-D-(1-->2)-linked series released from the phosphopeptidomannan of Candida albicans VW.32 (serotype A). Carbohydr. Res. 1992, 236, 17–27. [Google Scholar] [CrossRef] [PubMed]
  14. Faille, C.; Wieruszeski, J.M.; Lepage, G.; Michalski, J.C.; Poulain, D.; Strecker, G. 1H-NMR spectroscopy of manno-oligosaccharides of the beta-1,2-linked series released from the phosphopeptidomannan of Candida albicans VW-32 (serotype A). Biochem. Biophys. Res. Commun. 1991, 181, 1251–1258. [Google Scholar] [CrossRef]
  15. Faille, C.; Michalski, J.C.; Strecker, G.; Mackenzie, D.W.; Camus, D.; Poulain, D. Immunoreactivity of neoglycolipids constructed from oligomannosidic residues of the Candida albicans cell wall. Infect. Immun. 1990, 58, 3537–3544. [Google Scholar] [CrossRef]
  16. Faille, C.; Mackenzie, D.W.; Michalski, J.C.; Poulain, D. Evaluation of an enzyme immunoassay using neoglycolipids constructed from Candida albicans oligomannosides to define the specificity of anti-mannan antibodies. Eur. J. Clin. Microbiol. Infect. Dis. 1992, 11, 438–446. [Google Scholar] [CrossRef] [PubMed]
  17. Trinel, P.A.; Lepage, G.; Jouault, T.; Strecker, G.; Poulain, D. Definitive chemical evidence for the constitutive ability of Candida albicans serotype A strains to synthesize beta-1,2 linked oligomannosides containing up to 14 mannose residues. FEBS Lett. 1997, 416, 203–206. [Google Scholar] [CrossRef]
  18. Shibata, N.; Arai, M.; Haga, E.; Kikuchi, T.; Najima, M.; Satoh, T.; Kobayashi, H.; Suzuki, S. Structural identification of an epitope of antigenic factor 5 in mannans of Candida albicans NIH B-792 (serotype B) and J-1012 (serotype A) as beta-1,2-linked oligomannosyl residues. Infect. Immun. 1992, 60, 4100–4110. [Google Scholar] [CrossRef]
  19. Kobayashi, H.; Giummelly, P.; Takahashi, S.; Ishida, M.; Sato, J.; Takaku, M.; Nishidate, Y.; Shibata, N.; Okawa, Y.; Suzuki, S. Candida albicans serotype A strains grow in yeast extract-added Sabouraud liquid medium at pH 2.0, elaborating mannans without beta-1,2 linkage and phosphate group. Biochem. Biophys. Res. Commun. 1991, 175, 1003–1009. [Google Scholar] [CrossRef]
  20. Okawa, Y.; Takahata, T.; Kawamata, M.; Miyauchi, M.; Shibata, N.; Suzuki, A.; Kobayashi, H.; Suzuki, S. Temperature-dependent change of serological specificity of Candida albicans NIH A-207 cells cultured in yeast extract-added Sabouraud liquid medium: Disappearance of surface antigenic factors 4, 5, and 6 at high temperature. FEBS Lett. 1994, 345, 167–171. [Google Scholar] [CrossRef]
  21. Shibata, N.; Suzuki, A.; Kobayashi, H.; Okawa, Y. Chemical structure of the cell-wall mannan of Candida albicans serotype A and its difference in yeast and hyphal forms. Biochem. J. 2007, 404, 365–372. [Google Scholar] [CrossRef]
  22. Poulain, D.; Jouault, T.; Trinel, P. Immunoreactivity of Candida albicans b-1,2 Linked Oligomannosides and Phospholipomannan. In Fungal Cells in Biodefense Mechanisms; Suzuki, S., Suzuki, E.M., Eds.; Saikon Publishing Co., Ltd.: Tokyo, Japan, 1997; pp. 175–181. [Google Scholar]
  23. Trinel, P.A.; Faille, C.; Jacquinot, P.M.; Cailliez, J.C.; Poulain, D. Mapping of Candida albicans oligomannosidic epitopes by using monoclonal antibodies. Infect. Immun. 1992, 60, 3845–3851. [Google Scholar] [CrossRef]
  24. Cantelli, C.; Trinel, P.A.; Bernigaud, A.; Jouault, T.; Polonelli, L.; Poulain, D. Mapping of beta-1,2-linked oligomannosidic epitopes among glycoconjugates of Candida species. Microbiology 1995, 141 Pt 10, 2693–2697. [Google Scholar] [CrossRef] [PubMed]
  25. Trinel, P.A.; Borg-von-Zepelin, M.; Lepage, G.; Jouault, T.; Mackenzie, D.; Poulain, D. Isolation and preliminary characterization of the 14- to 18-kilodalton Candida albicans antigen as a phospholipomannan containing beta-1,2-linked oligomannosides. Infect. Immun. 1993, 61, 4398–4405. [Google Scholar] [CrossRef] [PubMed]
  26. Poulain, D.; Faille, C.; Delaunoy, C.; Jacquinot, P.M.; Trinel, P.A.; Camus, D. Probable presence of beta(1-2)-linked oligomannosides that act as human immunoglobulin G3 epitopes and are distributed over a Candida albicans 14- to 18-kilodalton antigen. Infect. Immun. 1993, 61, 1164–1166. [Google Scholar] [CrossRef] [PubMed]
  27. Trinel, P.A.; Cantelli, C.; Bernigaud, A.; Jouault, T.; Poulain, D. Evidence for different mannosylation processes involved in the association of beta-1,2-linked oligomannosidic epitopes in Candida albicans mannan and phospholipomannan. Microbiology 1996, 142 Pt 8, 2263–2270. [Google Scholar] [CrossRef]
  28. Trinel, P.A.; Plancke, Y.; Gerold, P.; Jouault, T.; Delplace, F.; Schwarz, R.T.; Strecker, G.; Poulain, D. The Candida albicans phospholipomannan is a family of glycolipids presenting phosphoinositolmannosides with long linear chains of beta-1,2-linked mannose residues. J. Biol. Chem. 1999, 274, 30520–30526. [Google Scholar] [CrossRef]
  29. Mille, C.; Janbon, G.; Delplace, F.; Ibata-Ombetta, S.; Gaillardin, C.; Strecker, G.; Jouault, T.; Trinel, P.A.; Poulain, D. Inactivation of CaMIT1 inhibits Candida albicans phospholipomannan beta-mannosylation, reduces virulence, and alters cell wall protein beta-mannosylation. J. Biol. Chem. 2004, 279, 47952–47960. [Google Scholar] [CrossRef]
  30. Fradin, C.; Slomianny, M.C.; Mille, C.; Masset, A.; Robert, R.; Sendid, B.; Ernst, J.F.; Michalski, J.C.; Poulain, D. Beta-1,2 oligomannose adhesin epitopes are widely distributed over the different families of Candida albicans cell wall mannoproteins and are associated through both N- and O-glycosylation processes. Infect. Immun. 2008, 76, 4509–4517. [Google Scholar] [CrossRef]
  31. Roman, E.; Correia, I.; Salazin, A.; Fradin, C.; Jouault, T.; Poulain, D.; Liu, F.T.; Pla, J. The Cek1-mediated MAP kinase pathway regulates exposure of alpha-1,2 and beta-1,2-mannosides in the cell wall of Candida albicans modulating immune recognition. Virulence 2016, 7, 558–577. [Google Scholar] [CrossRef]
  32. Mille, C.; Bobrowicz, P.; Trinel, P.A.; Li, H.; Maes, E.; Guerardel, Y.; Fradin, C.; Martinez-Esparza, M.; Davidson, R.C.; Janbon, G.; et al. Identification of a new family of genes involved in beta-1,2-mannosylation of glycans in Pichia pastoris and Candida albicans. J. Biol. Chem. 2008, 283, 9724–9736. [Google Scholar] [CrossRef]
  33. Mille, C.; Fradin, C.; Delplace, F.; Trinel, P.A.; Masset, A.; Francois, N.; Coddeville, B.; Bobrowicz, P.; Jouault, T.; Guerardel, Y.; et al. Members 5 and 6 of the Candida albicans BMT family encode enzymes acting specifically on beta-mannosylation of the phospholipomannan cell-wall glycosphingolipid. Glycobiology 2012, 22, 1332–1342. [Google Scholar] [CrossRef] [PubMed]
  34. Courjol, F.; Jouault, T.; Mille, C.; Hall, R.; Maes, E.; Sendid, B.; Mallet, J.M.; Guerardel, Y.; Gow, N.A.; Poulain, D.; et al. beta-1,2-Mannosyltransferases 1 and 3 Participate in Yeast and Hyphae O- and N-Linked Mannosylation and Alter Candida albicans Fitness During Infection. Open Forum Infect. Dis. 2015, 2, ofv116. [Google Scholar] [CrossRef] [PubMed]
  35. Cattiaux, L.; Mee, A.; Pourcelot, M.; Sfihi-Loualia, G.; Hurtaux, T.; Maes, E.; Fradin, C.; Sendid, B.; Poulain, D.; Fabre, E.; et al. Candida albicans beta-1,2 mannosyl transferase Bmt3: Preparation and evaluation of a beta (1,2), alpha (1,2)-tetramannosyl fluorescent substrate. Bioorg. Med. Chem. 2016, 24, 1362–1368. [Google Scholar] [CrossRef]
  36. Sfihi-Loualia, G.; Hurtaux, T.; Fabre, E.; Fradin, C.; Mee, A.; Pourcelot, M.; Maes, E.; Bouckaert, J.; Mallet, J.M.; Poulain, D.; et al. Candida albicans beta-1,2-mannosyltransferase Bmt3 prompts the elongation of the cell-wall phosphopeptidomannan. Glycobiology 2016, 26, 203–214. [Google Scholar] [CrossRef] [PubMed]
  37. Singh, R.P.; Prasad, H.K.; Sinha, I.; Agarwal, N.; Natarajan, K. Cap2-HAP complex is a critical transcriptional regulator that has dual but contrasting roles in regulation of iron homeostasis in Candida albicans. J. Biol. Chem. 2011, 286, 25154–25170. [Google Scholar] [CrossRef]
  38. Chen, C.; Pande, K.; French, S.D.; Tuch, B.B.; Noble, S.M. An iron homeostasis regulatory circuit with reciprocal roles in Candida albicans commensalism and pathogenesis. Cell Host Microbe 2011, 10, 118–135. [Google Scholar] [CrossRef]
  39. Bruno, M.; Kersten, S.; Bain, J.M.; Jaeger, M.; Rosati, D.; Kruppa, M.D.; Lowman, D.W.; Rice, P.J.; Graves, B.; Ma, Z.; et al. Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris. Nat. Microbiol. 2020, 5, 1516–1531. [Google Scholar] [CrossRef]
  40. Han, Y.; Riesselman, M.H.; Cutler, J.E. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect. Immun. 2000, 68, 1649–1654. [Google Scholar] [CrossRef]
  41. Rosario-Colon, J.; Eberle, K.; Adams, A.; Courville, E.; Xin, H. Candida Cell-Surface-Specific Monoclonal Antibodies Protect Mice against Candida auris Invasive Infection. Int. J. Mol. Sci. 2021, 22, 6162. [Google Scholar] [CrossRef]
  42. Doron, I.; Leonardi, I.; Li, X.V.; Fiers, W.D.; Semon, A.; Bialt-DeCelie, M.; Migaud, M.; Gao, I.H.; Lin, W.Y.; Kusakabe, T.; et al. Human gut mycobiota tune immunity via CARD9-dependent induction of anti-fungal IgG antibodies. Cell 2021, 184, 1017–1031 e1014. [Google Scholar] [CrossRef]
  43. She, X.; Zhang, P.; Shi, D.; Peng, J.; Wang, Q.; Meng, X.; Jiang, Y.; Calderone, R.; Bellanti, J.A.; Liu, W.; et al. The mitochondrial complex I proteins of Candida albicans moderate phagocytosis and the production of pro-inflammatory cytokines in murine macrophages and dendritic cells. FASEB J. 2022, 36, e22575. [Google Scholar] [CrossRef]
  44. Fruit, J.; Cailliez, J.C.; Odds, F.C.; Poulain, D. Expression of an epitope by surface glycoproteins of Candida albicans. Variability among species, strains and yeast cells of the genus Candida. J. Med. Vet. Mycol. 1990, 28, 241–252. [Google Scholar] [CrossRef] [PubMed]
  45. Trinel, P.A.; Jouault, T.; Cutler, J.E.; Poulain, D. Beta-1,2-mannosylation of Candida albicans mannoproteins and glycolipids differs with growth temperature and serotype. Infect. Immun. 2002, 70, 5274–5278. [Google Scholar] [CrossRef]
  46. Poulain, D.; Slomianny, C.; Jouault, T.; Gomez, J.M.; Trinel, P.A. Contribution of phospholipomannan to the surface expression of beta-1,2-oligomannosides in Candida albicans and its presence in cell wall extracts. Infect. Immun. 2002, 70, 4323–4328. [Google Scholar] [CrossRef]
  47. Jouault, T.; Fradin, C.; Trinel, P.A.; Bernigaud, A.; Poulain, D. Early signal transduction induced by Candida albicans in macrophages through shedding of a glycolipid. J. Infect. Dis. 1998, 178, 792–802. [Google Scholar] [CrossRef] [PubMed]
  48. Cailliez, J.C.; Boudrissa, A.; Mackenzie, D.W.; Poulain, D. Evaluation of a gold-silver staining method for detection and identification of Candida species by light microscopy. Eur. J. Clin. Microbiol. Infect. Dis. 1990, 9, 886–891. [Google Scholar] [CrossRef] [PubMed]
  49. Jawhara, S.; Thuru, X.; Standaert-Vitse, A.; Jouault, T.; Mordon, S.; Sendid, B.; Desreumaux, P.; Poulain, D. Colonization of mice by Candida albicans is promoted by chemically induced colitis and augments inflammatory responses through galectin-3. J. Infect. Dis. 2008, 197, 972–980. [Google Scholar] [CrossRef]
  50. Charlet, R.; Pruvost, Y.; Tumba, G.; Istel, F.; Poulain, D.; Kuchler, K.; Sendid, B.; Jawhara, S. Remodeling of the Candida glabrata cell wall in the gastrointestinal tract affects the gut microbiota and the immune response. Sci. Rep. 2018, 8, 3316. [Google Scholar] [CrossRef]
  51. Poulain, D.; Cailliez, J.C.; Dubremetz, J.F. Secretion of glycoproteins through the cell wall of Candida albicans. Eur. J. Cell Biol. 1989, 50, 94–99. [Google Scholar] [PubMed]
  52. Cailliez, J.C.; Poulain, D. Cytologic analysis of the expression of an epitope carried by glycoproteins excreted by Candida albicans. Ann. Inst. Pasteur Microbiol. 1988, 139, 171–188. [Google Scholar] [CrossRef] [PubMed]
  53. Han, Y.; Kanbe, T.; Cherniak, R.; Cutler, J.E. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect. Immun. 1997, 65, 4100–4107. [Google Scholar] [CrossRef] [PubMed]
  54. Rehaume, L.M.; Jouault, T.; Chamaillard, M. Lessons from the inflammasome: A molecular sentry linking Candida and Crohn’s disease. Trends Immunol. 2010, 31, 171–175. [Google Scholar] [CrossRef] [PubMed]
  55. Jouault, T.; Lepage, G.; Bernigaud, A.; Trinel, P.A.; Fradin, C.; Wieruszeski, J.M.; Strecker, G.; Poulain, D. Beta-1,2-linked oligomannosides from Candida albicans act as signals for tumor necrosis factor alpha production. Infect. Immun. 1995, 63, 2378–2381. [Google Scholar] [CrossRef]
  56. Jouault, T.; Ibata-Ombetta, S.; Takeuchi, O.; Trinel, P.A.; Sacchetti, P.; Lefebvre, P.; Akira, S.; Poulain, D. Candida albicans phospholipomannan is sensed through toll-like receptors. J. Infect. Dis. 2003, 188, 165–172. [Google Scholar] [CrossRef]
  57. Jouault, T.; Fradin, C.; Bernigaud, A.; Trinel, P.A.; Poulain, D. Interaction of Candida albicans with macrophages through phospholipomannan. Immunol. Lett. 1997, 56, 115–116. [Google Scholar] [CrossRef]
  58. Jouault, T.; Bernigaud, A.; Lepage, G.; Trinel, P.A.; Poulain, D. The Candida albicans phospholipomannan induces in vitro production of tumour necrosis factor-alpha from human and murine macrophages. Immunology 1994, 83, 268–273. [Google Scholar]
  59. Ibata-Ombetta, S.; Idziorek, T.; Trinel, P.A.; Poulain, D.; Jouault, T. Candida albicans phospholipomannan promotes survival of phagocytosed yeasts through modulation of bad phosphorylation and macrophage apoptosis. J. Biol. Chem. 2003, 278, 13086–13093. [Google Scholar] [CrossRef]
  60. Fradin, C.; Poulain, D.; Jouault, T. beta-1,2-linked oligomannosides from Candida albicans bind to a 32-kilodalton macrophage membrane protein homologous to the mammalian lectin galectin-3. Infect. Immun. 2000, 68, 4391–4398. [Google Scholar] [CrossRef]
  61. Fradin, C.; Jouault, T.; Mallet, A.; Mallet, J.M.; Camus, D.; Sinay, P.; Poulain, D. Beta-1,2-linked oligomannosides inhibit Candida albicans binding to murine macrophage. J. Leukoc. Biol. 1996, 60, 81–87. [Google Scholar] [CrossRef]
  62. Dromer, F.; Chevalier, R.; Sendid, B.; Improvisi, L.; Jouault, T.; Robert, R.; Mallet, J.M.; Poulain, D. Synthetic analogues of beta-1,2 oligomannosides prevent intestinal colonization by the pathogenic yeast Candida albicans. Antimicrob. Agents Chemother. 2002, 46, 3869–3876. [Google Scholar] [CrossRef]
  63. Dalle, F.; Jouault, T.; Trinel, P.A.; Esnault, J.; Mallet, J.M.; d’Athis, P.; Poulain, D.; Bonnin, A. Beta-1,2- and alpha-1,2-linked oligomannosides mediate adherence of Candida albicans blastospores to human enterocytes in vitro. Infect. Immun. 2003, 71, 7061–7068. [Google Scholar] [CrossRef] [PubMed]
  64. ten Oever, J.; Giamarellos-Bourboulis, E.J.; van de Veerdonk, F.L.; Stelma, F.F.; Simon, A.; Janssen, M.; Johnson, M.; Pachot, A.; Kullberg, B.J.; Joosten, L.A.; et al. Circulating galectin-3 in infections and non-infectious inflammatory diseases. Eur. J. Clin. Microbiol. Infect. Dis. 2013, 32, 1605–1610. [Google Scholar] [CrossRef] [PubMed]
  65. Sendid, B.; Salvetat, N.; Sarter, H.; Loridant, S.; Cunisse, C.; Francois, N.; Aijjou, R.; Gele, P.; Leroy, J.; Deplanque, D.; et al. A Pilot Clinical Study on Post-Operative Recurrence Provides Biological Clues for a Role of Candida Yeasts and Fluconazole in Crohn’s Disease. J. Fungi 2021, 7, 324. [Google Scholar] [CrossRef] [PubMed]
  66. Warr, G.A. A macrophage receptor for (mannose/glucosamine)-glycoproteins of potential importance in phagocytic activity. Biochem. Biophys. Res. Commun. 1980, 93, 737–745. [Google Scholar] [CrossRef] [PubMed]
  67. Stahl, P.; Schlesinger, P.H.; Sigardson, E.; Rodman, J.S.; Lee, Y.C. Receptor-mediated pinocytosis of mannose glycoconjugates by macrophages: Characterization and evidence for receptor recycling. Cell 1980, 19, 207–215. [Google Scholar] [CrossRef] [PubMed]
  68. Neth, O.; Jack, D.L.; Dodds, A.W.; Holzel, H.; Klein, N.J.; Turner, M.W. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect. Immun. 2000, 68, 688–693. [Google Scholar] [CrossRef]
  69. Yokota, K.; Takashima, A.; Bergstresser, P.R.; Ariizumi, K. Identification of a human homologue of the dendritic cell-associated C-type lectin-1, dectin-1. Gene 2001, 272, 51–60. [Google Scholar] [CrossRef]
  70. Hermanz-Falcon, P.; Arce, I.; Roda-Navarro, P.; Fernandez-Ruiz, E. Cloning of human DECTIN-1, a novel C-type lectin-like receptor gene expressed on dendritic cells. Immunogenetics 2001, 53, 288–295. [Google Scholar] [CrossRef]
  71. Brown, G.D.; Herre, J.; Williams, D.L.; Willment, J.A.; Marshall, A.S.; Gordon, S. Dectin-1 mediates the biological effects of beta-glucans. J. Exp. Med. 2003, 197, 1119–1124. [Google Scholar] [CrossRef]
  72. Tada, H.; Nemoto, E.; Shimauchi, H.; Watanabe, T.; Mikami, T.; Matsumoto, T.; Ohno, N.; Tamura, H.; Shibata, K.; Akashi, S.; et al. Saccharomyces cerevisiae- and Candida albicans-derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD14- and Toll-like receptor 4-dependent manner. Microbiol. Immunol. 2002, 46, 503–512. [Google Scholar] [CrossRef]
  73. Netea, M.G.; Van Der Graaf, C.A.; Vonk, A.G.; Verschueren, I.; Van Der Meer, J.W.; Kullberg, B.J. The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated candidiasis. J. Infect. Dis. 2002, 185, 1483–1489. [Google Scholar] [CrossRef]
  74. Cambi, A.; Gijzen, K.; de Vries, I.J.M.; Torensma, R.; Joosten, B.; Adema, G.J.; Netea, M.G.; Kullberg, B.J.; Romani, L.; Figdor, C.G. The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur. J. Immunol. 2003, 33, 532–538. [Google Scholar] [CrossRef] [PubMed]
  75. Sato, K.; Yang, X.L.; Yudate, T.; Chung, J.S.; Wu, J.; Luby-Phelps, K.; Kimberly, R.P.; Underhill, D.; Cruz, P.D., Jr.; Ariizumi, K. Dectin-2 is a pattern recognition receptor for fungi that couples with the Fc receptor gamma chain to induce innate immune responses. J. Biol. Chem. 2006, 281, 38854–38866. [Google Scholar] [CrossRef] [PubMed]
  76. McGreal, E.P.; Rosas, M.; Brown, G.D.; Zamze, S.; Wong, S.Y.; Gordon, S.; Martinez-Pomares, L.; Taylor, P.R. The carbohydrate-recognition domain of Dectin-2 is a C-type lectin with specificity for high mannose. Glycobiology 2006, 16, 422–430. [Google Scholar] [CrossRef]
  77. Hontelez, S.; Sanecka, A.; Netea, M.G.; van Spriel, A.B.; Adema, G.J. Molecular view on PRR cross-talk in antifungal immunity. Cell Microbiol. 2012, 14, 467–474. [Google Scholar] [CrossRef] [PubMed]
  78. Netea, M.G.; Joosten, L.A.; van der Meer, J.W.; Kullberg, B.J.; van de Veerdonk, F.L. Immune defence against Candida fungal infections. Nat. Rev. Immunol. 2015, 15, 630–642. [Google Scholar] [CrossRef]
  79. Poulain, D.; Jouault, T. Candida albicans cell wall glycans, host receptors and responses: Elements for a decisive crosstalk. Curr. Opin. Microbiol. 2004, 7, 342–349. [Google Scholar] [CrossRef]
  80. Ueno, K.; Okawara, A.; Yamagoe, S.; Naka, T.; Umeyama, T.; Utena-Abe, Y.; Tarumoto, N.; Niimi, M.; Ohno, H.; Doe, M.; et al. The mannan of Candida albicans lacking beta-1,2-linked oligomannosides increases the production of inflammatory cytokines by dendritic cells. Med. Mycol. 2013, 51, 385–395. [Google Scholar] [CrossRef]
  81. Standaert-Vitse, A.; Jouault, T.; Vandewalle, P.; Mille, C.; Seddik, M.; Sendid, B.; Mallet, J.M.; Colombel, J.F.; Poulain, D. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn’s disease. Gastroenterology 2006, 130, 1764–1775. [Google Scholar] [CrossRef]
  82. Rinaldi, M.; Perricone, R.; Blank, M.; Perricone, C.; Shoenfeld, Y. Anti-Saccharomyces cerevisiae autoantibodies in autoimmune diseases: From bread baking to autoimmunity. Clin. Rev. Allergy Immunol. 2013, 45, 152–161. [Google Scholar] [CrossRef]
  83. Collot, M.; Sendid, B.; Fievez, A.; Savaux, C.; Standaert-Vitse, A.; Tabouret, M.; Drucbert, A.S.; Danze, P.M.; Poulain, D.; Mallet, J.M. Biotin sulfone as a new tool for synthetic oligosaccharide immobilization: Application to multiple analysis profiling and surface plasmonic analysis of anti-Candida albicans antibody reactivity against alpha and beta (1-->2) oligomannosides. J. Med. Chem. 2008, 51, 6201–6210. [Google Scholar] [CrossRef] [PubMed]
  84. Sendid, B.; Lecointe, K.; Collot, M.; Danze, P.M.; Damiens, S.; Drucbert, A.S.; Fradin, C.; Vilcot, J.P.; Grenouillet, F.; Dubar, F.; et al. Dissection of the anti-Candida albicans mannan immune response using synthetic oligomannosides reveals unique properties of beta-1,2 mannotriose protective epitopes. Sci. Rep. 2021, 11, 10825. [Google Scholar] [CrossRef] [PubMed]
  85. Jouault, T.; Fradin, C.; Dzierszinski, F.; Borg-Von-Zepelin, M.; Tomavo, S.; Corman, R.; Trinel, P.A.; Kerckaert, J.P.; Poulain, D. Peptides that mimic Candida albicans-derived beta-1,2-linked mannosides. Glycobiology 2001, 11, 693–701. [Google Scholar] [CrossRef]
  86. Poulain, D.; Mackenzie, D.W.; Van Cutsem, J. Monoclonal antibody-gold silver staining dot assay for the detection of antigenaemia in candidosis. Mycoses 1991, 34, 221–226. [Google Scholar] [CrossRef]
  87. Poulain, D.; Deveaux, M.; Cailliez, J.C.; Hossein-Foucher, C.; Dutoit, E.; Camus, D.; Van Cutsem, J.; Marchandise, X. Imaging of systemic Candida albicans infections with a radioiodinated monoclonal antibody: Experimental study in the guinea pig. Int. J. Radiat. Appl. Instrum. Part B Nucl. Med. Biol. 1991, 18, 677–686. [Google Scholar] [CrossRef]
  88. Sendid, B.; Poirot, J.L.; Tabouret, M.; Bonnin, A.; Caillot, D.; Camus, D.; Poulain, D. Combined detection of mannanaemia and antimannan antibodies as a strategy for the diagnosis of systemic infection caused by pathogenic Candida species. J. Med. Microbiol. 2002, 51, 433–442. [Google Scholar] [CrossRef]
  89. Poulain, D.; Robert, R.; Mesnard, F.; Sendid, B.; Lepage, G.; Camus, D. Clearances of Candida albicans-derived alpha- and beta-linked mannose residues in sera from patients with candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 1997, 16, 16–20. [Google Scholar] [CrossRef]
  90. Zheng, H.; Chen, X.; Li, W.; Lu, J.; Chen, X. Establishment of a Fast Diagnostic Method for Sepsis Pathogens Based on M1 Bead Enrichment. Curr. Microbiol. 2023, 80, 166. [Google Scholar] [CrossRef]
  91. Apaire-Marchais, V.; Kempf, M.; Lefrancois, C.; Marot, A.; Licznar, P.; Cottin, J.; Poulain, D.; Robert, R. Evaluation of an immunomagnetic separation method to capture Candida yeasts cells in blood. BMC Microbiol. 2008, 8, 157. [Google Scholar] [CrossRef] [PubMed]
  92. Martinez-Esparza, M.; Sarazin, A.; Jouy, N.; Poulain, D.; Jouault, T. Comparative analysis of cell wall surface glycan expression in Candida albicans and Saccharomyces cerevisiae yeasts by flow cytometry. J. Immunol. Methods 2006, 314, 90–102. [Google Scholar] [CrossRef] [PubMed]
  93. Gangneux, J.P.; Cornet, M.; Bailly, S.; Fradin, C.; Feger, C.; Timsit, J.F.; Leroy, O.; Sendid, B.; Bougnoux, M.E. Clinical Impact of Antifungal Susceptibility, Biofilm Formation and Mannoside Expression of Candida Yeasts on the Outcome of Invasive Candidiasis in ICU: An Ancillary Study on the Prospective AmarCAND2 Cohort. Front. Microbiol. 2018, 9, 2907. [Google Scholar] [CrossRef] [PubMed]
  94. Robert, R.; Tronchin, G.; Annaix, V.; Bouali, A.; Senet, J.M. Use of coated latex particles for identification and localization of Candida albicans cell surface receptors and for detection of related circulating antigens and/or antibodies in patient sera and urine. Target. Diagn. Ther. 1989, 2, 217–230. [Google Scholar]
  95. Marot-Leblond, A.; Nail-Billaud, S.; Pilon, F.; Beucher, B.; Poulain, D.; Robert, R. Efficient diagnosis of vulvovaginal candidiasis by use of a new rapid immunochromatography test. J. Clin. Microbiol. 2009, 47, 3821–3825. [Google Scholar] [CrossRef] [PubMed]
  96. Courjol, F.; Mille, C.; Hall, R.A.; Masset, A.; Aijjou, R.; Gow, N.A.; Poulain, D.; Jouault, T.; Fradin, C. Initiation of phospholipomannan beta-1,2 mannosylation involves Bmts with redundant activity, influences its cell wall location and regulates beta-glucans homeostasis but is dispensable for Candida albicans systemic infection. Biochimie 2016, 120, 96–104. [Google Scholar] [CrossRef]
  97. Sendid, B.; Jouault, T.; Coudriau, R.; Camus, D.; Odds, F.; Tabouret, M.; Poulain, D. Increased sensitivity of mannanemia detection tests by joint detection of alpha- and beta-linked oligomannosides during experimental and human systemic candidiasis. J. Clin. Microbiol. 2004, 42, 164–171. [Google Scholar] [CrossRef]
  98. Sobel, J.D. Vulvovaginal candidosis. Lancet 2007, 369, 1961–1971. [Google Scholar] [CrossRef]
  99. Casadevall, A.; Pirofski, L.A. The damage-response framework of microbial pathogenesis. Nat. Rev. Microbiol. 2003, 1, 17–24. [Google Scholar] [CrossRef] [PubMed]
Jof 09 00636 g001 550
Figure 1. Schematized representation of the different achievements in basic and clinical research gathered over time by the use of mAb 5B2. The numbers in superscripts correspond to the studies described and referenced in the text.
Figure 1. Schematized representation of the different achievements in basic and clinical research gathered over time by the use of mAb 5B2. The numbers in superscripts correspond to the studies described and referenced in the text.
Jof 09 00636 g001
Table
Table 1. List of technologies involving mAb 5B2 depending on the objectives of the different studies reported in the review.
Table 1. List of technologies involving mAb 5B2 depending on the objectives of the different studies reported in the review.
TechnologiesObjectiveAchievementReferences
BASIC IMMUNOCHEMISTRY/IN VITRO ANALYSIS
ELISA inhibition
C. albicans phosphopeptidomannan as substrate and inhibition by oligoammnosides released by sequential depolymerization		To identify mAb 5B2 epitopeIdentification of mAb 5B2 epitope among the β-mannopyranosyl series[13,14,15,16,17]
Reactivity with neoglycolipids Development of method for constructing neoglycolipids to study the roles of oligomannoside sequences in the antigenicity of C. albicans phosphopeptidomannanConfirmation with monospecific rabbit polyclonal IgG
Flow cytometryTo differentially probe C. albicans surface glycans over a yeast population
To study the remodeling of the C. glabrata cell wall in the gastrointestinal tract		Ability of C. albicans to regulate its glycan surface expression and therefore modify its virulence properties
Evidence that inflammation of the gut alters the microbial balance and remodels C. glabrata cell wall		[50,92]
Phage displayTo seek for peptides sequences mimicking 5B2 epitopeIdentification of a peptide sequence mimicking antigenicity and immunogenicity of the β-oligomannose epitope[85]
Plasmon magnetic resonanceTo finely differentiate mAb B6.1 and mAb 5B2 epitopesIn contrast to mAb B6.1, mAb 5B2 does not cross react with α-1,2 linked mannosides[83,84]
Indirect immunofluorescence
confocal microscopy		To analyze the complexitiy of β-1,2 Mannoside epitope expression at C. albicans cell wall surfaceHeterogeneous and highly variable or patchy expression of 5B2 epitope at cell wall surface of different C. albicans growth forms[1,46,52]
Direct coupling to gold particles
Electron microscopy on frozen C. albicans sections		To analyze cell wall and cytoplasmic sub-cellular localization of mAb 5B2 epitopePresence of β-Mans in vesicles merging with the cell membrane, moving from periplasmic space to cell wall fimbriaes following channels within the cell wall[51,52]
Western blottingTo identify molecules expressing β-Man epitopes
and members of the BMT gene family responsible for sequential addition of β-Man on these substates 		Besides PPM, the epitope is shared by numerous mannoproteins[23]
High expression and specific patterns of distribution exist in C. albicans, tropicalis glabrata[9]
The epitope is shared by GPI anchored, PIR and secreted major C. albicans virulence factors[30]
The epitope allows characterization of a glycolipid named phopholipomannan, a member of the manno-inositol family with strong immunomodulatory properties[29,32,45]
Discovery of BMT gene family responsible for synthesis of β-mannosides composed of 9 members and precise definition of Bmts 1–6 activities depending on the acceptor molecule[32,33,96]
IN VIVO ANALYSIS
Imaging after radio-iodinationTo detect in vivo Candida infectious foci by using of radioiodinated monoclonal antibodyThe biodistribution of 131I radioactivity was greater in infected animals than in healthy animals and increased as a function of the number of CFU per g in each organ[87]
Immunogold silver staining histopathologyTo detect Candida species cells in tissue sections or during direct examination on glass slideThe method is sensitive with good definition, rapid and easy to perform. Long conservation of samples for collections[48]
CLINICAL APPLICATIONS
Immunogold silver staining dot blot of animal and human seraTo investigate the ability of mAb 5B2 to detect circulating antigens in sera of animals experimentally infected by C. albicans and in sera of patients with invasive candidiasisThe method, easy to perform, is adapted to the screening of large number of patients under serological surveillance[86]
Sandwich ELISA for immunocaptureTo improve the sensitivity of invasive candidiasis diagnosis by joint detection of α and β-mannosidesProvide evidence for different kinetics of β and α-Man circulation during experimental and human candidiasis[97]
Development of a method for immunomagnetic capture of Candida cells in bloodTo increase the sensitivity of blood cultureThe method saves at least 24 h to obtain colonies by comparison to automated blood cultures[91]
Immunochromatographic testTo diagnose vulvo-vaginal candidiasisPoint of care test adapted to the management of women with symptoms of vaginitis and differentiate colonization from infection[95]
EPIDEMIOLOGY/PATHOGENICITY MARKER
Direct agglutination of isolated C. albicans strainsTo seek for differences in strain pathogenic potentialHigher expression in strains isolated in pathogenic vs. saprophytic conditions in human[44]
ELISA after coating of isolated C. albicans strainsTo investigate the correlation between yeast strain phenotypical features and patient outcomeHigher expression of β-Man detected by mAb 5B2 is related to increased patient mortality[93]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Leroy, J.; Lecointe, K.; Coulon, P.; Sendid, B.; Robert, R.; Poulain, D. Antibodies as Models and Tools to Decipher Candida albicans Pathogenic Development: Review about a Unique Monoclonal Antibody Reacting with Immunomodulatory Adhesins. J. Fungi 2023, 9, 636. https://doi.org/10.3390/jof9060636

AMA Style

Leroy J, Lecointe K, Coulon P, Sendid B, Robert R, Poulain D. Antibodies as Models and Tools to Decipher Candida albicans Pathogenic Development: Review about a Unique Monoclonal Antibody Reacting with Immunomodulatory Adhesins. Journal of Fungi. 2023; 9(6):636. https://doi.org/10.3390/jof9060636

Chicago/Turabian Style

Leroy, Jordan, Karine Lecointe, Pauline Coulon, Boualem Sendid, Raymond Robert, and Daniel Poulain. 2023. "Antibodies as Models and Tools to Decipher Candida albicans Pathogenic Development: Review about a Unique Monoclonal Antibody Reacting with Immunomodulatory Adhesins" Journal of Fungi 9, no. 6: 636. https://doi.org/10.3390/jof9060636

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop